Recommendation Grading Strength of Recommendation
1 = strong 2 = weak
Quality of Evidence A = high
B = moderate C = low
Abbreviations
CA-MRSA, community-acquired methicillin-resistant Staphylococcus aureus; CWAA, cell-wall active agent; DFI, diabetic foot infection; DNAIA, DNA-inhibiting agent; FQN, fluoroquinolones; gen, generation; HA-MRSA, hospital-acquired methicillin-resistant Staphylococcus aureus; IVIg, intravenous immunoglobulin; lb, pound(s); MSSA, methicillin- sensitive Staphylococcus aureus; NSTI, necrotizing skin and soſt tissue infection; PSIA, protein synthesis-inhibiting agent; PVL, Panton-Valentine leukocidin toxin; SSTI, skin and soſt tissue infection; TSS, staphylococcal toxic shock syndrome
Source May AK, Stafford RE, Bulger EM, Heffernan D, Guillamondegui O, Bochicchio G, Eachempati SR. Treatment of complicated skin and soſt tissue infections. Surgical Infections. 2009;10(5):467-499.
Disclaimer
This Guideline attempts to define principles of practice that should produce high-quality patient care. It focuses on the needs of primary care practice, but also is applicable to providers at all levels. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aſter consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool.
5740 Executive Drive Suite 218 Baltimore, MD 21228 TEL: 410-869-3332 • FAX: 410-744-2150 For additional copies: orders@GuidelineCentral.com Copyright © 2010 All rights reserved
